Comparing robotic versus TaTME surgery for rectal cancer
Part of Cancer, Digestive system clinical trials.
This study compares two ways of performing rectal cancer surgery: robotic surgery and a newer technique called TaTME (transanal total mesorectal excision). It aims to see which approach has better outcomes for patients. If you're having surgery for rectal cancer, this trial might help you get access to advanced surgical options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have rectal cancer that is scheduled for TME surgery (surgery to remove the tumor and surrounding tissue) after discussion with your medical team.
- You must be 18 years or older.
- Your tumor must be located 12 cm or less from the anal verge (the opening of the rectum).
- You must be able to safely receive pelvic radiation therapy if needed.
- You must not be pregnant, breast-feeding, or planning to become pregnant during the trial.
- You must have a life expectancy of at least 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two different surgery approaches for early-stage rectal cancer (T2N0M0) that is close to the anus. It tests whether a less invasive local removal followed by radiation works as well as more extensive surgery (total mesorectal excision).
This trial compares a new surgery method that uses multiple technologies to remove rectal cancer more precisely versus the standard surgery. It is for people with middle or lower rectal cancer that hasn't spread, and it may help improve outcomes after surgery.
This trial compares two approaches for low-risk locally advanced rectal cancer: going straight to surgery (TME) versus receiving chemotherapy before surgery. The goal is to see if upfront surgery works just as well, sparing patients from chemotherapy side effects.
This study compares two ways of reconnecting the intestine after rectal cancer surgery. It looks at a newer method called TTSS against the standard double-stapled technique.
This trial looks at whether removing the rectal tumor locally (through the anus) can work as well as a more extensive operation after scans show no remaining cancer. It may help some people avoid bigger surgery if the cancer truly appears gone after treatment.
This trial compares standard chemotherapy to more extensive surgery (total mesorectal excision) for patients whose initial local surgery showed high-risk features like poor differentiation, lymphovascular invasion, or larger tumor size. It aims to find the best treatment to prevent cancer from coming back.
Hear when a new Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.